ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 18, 2025.

via HealthDay

FRIDAY, July 18, 2025 -- In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy care in individuals with preexisting diabetes mellitus (PDM). The guidelines were published online July 14 in the Journal of Clinical Endocrinology & Metabolism to coincide with presentation at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.

Jennifer A. Wyckoff, M.D., from the University of Michigan in Ann Arbor, and colleagues developed recommendations for the care of individuals with PDM before, during, and after pregnancy.

The authors suggest asking a screening question about pregnancy intention for individuals with diabetes mellitus who have the possibility of becoming pregnant, with contraception suggested when pregnancy is not desired. Discontinuation of glucagon-like peptide-1 receptor agonists is suggested before conception -- rather than between the start of pregnancy and the end of the first trimester -- in individuals with type 2 diabetes mellitus (T2DM). Routine addition of metformin is not suggested in pregnant individuals with T2DM already on insulin. Either a carbohydrate-restricted diet (<175 g/day) or usual diet (>175 g/day) is suggested during pregnancy in individuals with PDM. Use of a continuous glucose monitor (CGM) or self-monitoring of blood glucose is suggested in pregnant individuals with T2DM. For individuals with PDM using a CGM, use of a single 24-hour CGM target <140 mg/dL is not suggested in place of standard-of-care pregnancy glucose targets. A hybrid closed-loop pump is suggested rather than an insulin pump with CGM for individuals with type 1 diabetes mellitus who are pregnant.

"We developed these guidelines as diabetes rates are rising among women of reproductive age and very few women with diabetes receive proper preconception care," Wyckoff said in a statement.

Several authors disclosed financial ties to the pharmaceutical industry; two authors disclosed ties to Dexcom.

Abstract/Full Text

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords